Variable | Time (months) | Hospitalised (n=25) | Community (n=31) | P value | Recovered (n=13) | Symptomatic (n=43) | P value |
Age | 5 | 43.1±9.8 | 38.5±9.9 | 0.09 | 41.7±10.2 | 40.1±10.1 | 0.61 |
Sex (M/F ratio) | 5 | 0.92/0.08 | 0.81/0.19 | 0.28 | 0.92/0.08 | 0.84/0.16 | 0.67 |
Height | 5 | 176.8±6.8 | 177.5±9.4 | 0.74 | 176.9±7.36 | 177.3±8.7 | 0.89 |
Body mass (kg) | 5 | 96.0±13.1 | 88.5±14.9 | 0.05 | 87.0±17.1 | 93.3±13.4 | 0.16 |
12 | 98.1±16.3 | 88.9±13.2 | 0.02 | 88.5±18.5 | 94.4±14.0 | 0.21 | |
18 | 98.5±15.2 | 91.0±13.6 | 0.05 | 89.1±17.4 | 96.0±13.5 | 0.13 | |
BMI | 5 | 30.7±3.5 | 28.0±3.5 | 0.01 | 27.6±3.5 | 29.7±3.7 | 0.07 |
12 | 31.5±4.3 | 28.2±3.1 | <0.01 | 28.4±4.1 | 30.0±4.0 | 0.19 | |
18 | 32.0±4.4 | 28.8±3.2 | <0.01 | 28.5±4.1 | 30.8±3.9 | 0.07 | |
Waist circumference (cm) | 5 | 102.6±9.0 | 92.1±10.7 | <0.01 | 92.4±13.4 | 98.1±10.3 | 0.10 |
12 | 104.3±11.8 | 93.1±11.6 | <0.01 | 94.0±13.1 | 99.3±12.6 | 0.18 | |
18 | 106.3±11.7 | 96.7±9.5 | <0.01 | 94.8±13.9 | 102.9±10.0 | 0.02 | |
Hip circumference (cm) | 5 | 105.7±8.9 | 101.6±8.3 | 0.09 | 100.5±8.1 | 104.4±8.8 | 0.14 |
12 | 105.7±11.1 | 99.5±9.2 | 0.03 | 99.1±9.7 | 103.3±10.6 | 0.19 | |
18 | 106.6±9.3 | 101.5±7.6 | 0.03 | 99.0±9.3 | 105.3±8.0 | 0.02 | |
Waist:hip ratio | 5 | 0.91±0.08 | 0.97±0.06 | <0.01 | 0.92±0.08 | 0.94±0.08 | 0.33 |
12 | 0.94±0.9 | 0.99±0.05 | 0.02 | 0.95±0.06 | 0.96±0.09 | 0.52 | |
18 | 0.95±0.07 | 1.00±0.05 | 0.01 | 0.96±0.07 | 0.98±0.06 | 0.29 |
The 56 COVID-19-exposed participants can be classified into two, non-mutually exclusive groups according to their recovery status and acute severity. Of the 56 exposed participants, 25 were hospitalised during the acute stage of illness and 43 presented with at least one of the following six self-identified symptoms at 5 months post-acute stage of illness: fatigue, shortness of breath, chest pain, joint pain, exercise intolerance and anosmia.
BMI, body mass index; M/F, male/female.